MetaCap

electroCore (ECOR) vs iTonic (ITOC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

electroCore (ECOR) has outperformed iTonic (ITOC) over the past year, losing 6.2% versus a loss of 82.0%. electroCore is the larger company by market cap ($40.8 million vs $11.6 million), about 3.5 times the size. electroCore converts more of its revenue into profit, with a net margin of -43.6% versus -974.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ECOR-6.16%ITOC-81.96%
+173%+39%-95%
Nov 21, 20251 yearNov 20, 2026
ECOR-25.59%ITOC-97.45%
+685%+275%-135%
Sep 2, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ECOR versus ITOC key metrics
MetricECORITOC
Share price$4.42$1.59
Market cap$40.78M$11.63M
1-day change-8.87%+6.00%
YTD return-1.45%-76.40%
1-year return-6.16%-81.96%
5-year return-61.23%—
EPS (TTM)$-1.36$-4.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$32.03M$523.03K
Revenue growth (YoY)+27.20%+16.70%
Net income (latest FY)$-13.97M$-5.10M
Gross margin86.75%62.59%
Operating margin-41.06%-991.71%
Net margin-43.60%-974.68%
52-week high$12.70$18.40
52-week low$3.90$1.40
Distance from 52-week high-65.20%-91.36%
Analyst consensusnone—
Avg. price target upside+333.71%—
Average volume120.32K42.84K
Shares outstanding9.23M6.84M
Employees837
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • electroCore is about 3.5 times larger than iTonic by market value ($40.78M vs $11.63M).
  • ECOR has outperformed ITOC by 75.8 percentage points over the past year.
  • electroCore is more profitable, keeping -43.6 cents of every revenue dollar as net income versus -974.7 cents for iTonic.
  • electroCore grew revenue faster in its latest fiscal year (+27.20% vs +16.70%).

About electroCore

ECOR stock →

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 83 employees

About iTonic

ITOC stock →

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. The company's proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 7 employees

ECOR vs ITOC FAQ

Which is bigger, electroCore or iTonic?

electroCore (ECOR) is larger, with a market capitalization of $40.78M compared with $11.63M for iTonic (ITOC).

Which stock has performed better over the past year, ECOR or ITOC?

ECOR returned -6.16% over the past 12 months, compared with -81.96% for ITOC (price return, excluding dividends). Past performance does not predict future results.

Are electroCore and iTonic in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons